Skip to Main Content

Although Pfizer (PFE) agreed to make its Covid-19 pill available in 95 low and middle-income countries, the company is simultaneously filing patents in dozens of other nations representing nearly half of the global population, raising fresh questions about restricted access, according to a new report.

Such a patent strategy is expected given the potential for the pill, called Paxlovid, to generate significant revenue. Last week, Pfizer forecasted sales of $22 billion this year, although that could rise depending on whether additional contracts are signed or extended with countries not covered by the deal with the Medicines Patent Pool.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment